Berberine suppresses in vitro migration of human aortic smooth muscle cells through the inhibitions of MMP-2/9, u-PA, AP-1, and NF-κB

BMB Reports

Volumn 47, Issue 7, 2014, Pages 388-392

  Liu, Su jian ^a   Yin, Cai xia ^b   Ding, Ming chao ^a   Xia, Shao you ^b   Shen, Qin min ^c   Wu, Ji dong ^c  

^a AEROSPACE CENTER HOSPITAL   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c Beijing Aerospace General Hospital   (China)

Author keywords

Berberine; Human aortic smooth muscle cells; Matrix metalloproteinase; Migration; Restenosis

Indexed keywords

BERBERINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C FOS; PROTEIN C JUN; TRANSCRIPTION FACTOR AP 1; UROKINASE;

ANTAGONISTS AND INHIBITORS; CELL LINE; CELL MOTION; CHEMISTRY; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; HUMAN; METABOLISM; SMOOTH MUSCLE FIBER;

BERBERINE; CELL LINE; CELL MOVEMENT; DOWN-REGULATION; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; TRANSCRIPTION FACTOR AP-1; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84905918796     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.7.186     Document Type: Article

References (29)

1. Mills, B., Robb, T. and Larson, D. F. (2012) Intimal hyperplasia: slow but deadly. Perfusion 27, 520-528.
2. Bennett, M. R. (2003) In-stent stenosis: pathology and implications for the development of drug eluting stents. Heart 89, 218-224.
3. Lowe, H. C., Oesterle, S. N. and Khachigian, L. M. (2002) Coronary in-stent restenosis: current status and future strategies. J. Am. Coll. Cardiol. 39, 183-193.
4. Lafont, A. and Libby, P. (1998) The smooth muscle cell: sinner or saint in restenosis and the acute coronary syndromes? J. Am. Coll. Cardiol. 32, 283-285.
5. Gerthoffer, W. T. (2007) Mechanisms of vascular smooth muscle cell migration. Circ. Res. 100, 607-621.
6. Siefert, S. A. and Sarkar, R. (2012) Matrix metalloproteinases in vascular physiology and disease. Vascular 20, 210-216.
7. Johnson, J. L., Dwivedi, A., Somerville, M., George, S. J. and Newby, A. C. (2011) Matrix metalloproteinase (MMP)-3 activates MMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler. Thromb. Vasc. Biol. 31, 30.
8. Schiller, L. R. (1995) Review article: anti-diarrhoeal pharmacology and therapeutics. Aliment. Pharmacol. Ther. 9, 87-106.
9. Hwang, J.-M., Kuo, H.-C., Tseng, T.-H., Liu, J.-Y. and Chu, C.-Y. (2006) Berberine induces apoptosis through a mitochondria/ caspases pathway in human hepatoma cells. Arch. Toxicol. 80, 62-73.
10. Mahata, S., Bharti, A. C., Shukla, S., Tyagi, A., Husain, S. A. and Das, B. C. (2011) Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol. Cancer. 10, 39.
11. Li, X. K., Motwani, M., Tong, W., Bornmann, W. and Schwartz, G. K. (2000) Huanglian, A chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol. Pharmacol. 58, 1287-1293.
12. Nishino, H., Kitagawa, K., Fujiki, H. and Iwashima, A. (1986) Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 43, 131-134.
13. Pan, G. Y., Huang, Z. J., Wang, G. J., Fawcett, J. P., Liu, X. D., Zhao, X. C., Sun, J. G. and Xie, Y. Y. (2003) The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 69, 632-636.
14. Leng, S. H., Lu, F. E. and Xu, L. J. (2004) Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 25, 496-502.
15. Yin, J., Hu, R., Chen, M., Tang, J., Li, F., Yang, Y. and Chen, J. (2002) Effects of berberine on glucose metabolism in vitro. Metabolism 51, 1439-1443.
16. Hong, Y., Hui, S. S., Chan, B. T. and Hou, J. (2003) Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 72, 2499-2507.
17. Hong, Y., Hui, S. C., Chan, T. Y. and Hou, J. Y. (2002) Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am. J. Chin. Med. 30, 589-599.
18. Zeng, X. H., Zeng, X. J. and Li, Y. Y. (2003) Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. 92, 173-176.
19. Lee, S., Lim, H.-J., Park, H.-Y., Lee, K.-S., Park, J.-H. and Jang, Y. (2006) Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo: berberine improves neointima formation in a rat model. Atherosclerosis 186, 29-37.
20. Liang, K.-W., Ting, C.-T., Yin, S.-C., Chen, Y.-T., Lin, S.-J., Liao, J. K. and Hsu, S.-L. (2006) Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem. Pharmacol. 71, 806-817.
21. Chase, A. J. and Newby, A. C. (2003) Regulation of matrix metalloproteinase (matrixin) genes in blood vessels: a multi-step recruitment model for pathological remodelling. J. Vasc. Res. 40, 329-343.
22. Mason, D. P., Kenagy, R. D., Hasenstab, D., Bowen-Pope, D. F., Seifert, R. A., Coats, S., Hawkins, S. M. and Clowes, A. W. (1999) Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodeling in the injured rat carotid artery. Circ. Res. 85, 1179-1185.
23. Nelson, A. R., Fingleton, B., Rothenberg, M. L. and Matrisian, L. M. (2000) Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 18, 1135-1149.
24. Redmond, E. M., Cahill, P. A., Hirsch, M., Wang, Y. N., Sitzmann, J. V. and Okada, S. S. (1999) Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Thromb. Haemost. 81, 293-300.
25. Bond, M., Fabunmi, R. P., Baker, A. H. and Newby, A. C. (1998) Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-κB. FEBS Lett. 435, 29-34.
26. Zhang, H.-W., Wang, X., Zong, Z.-H., Huo, X. and Zhang, Q. (2009) AP-1 inhibits expression of MMP-2/9 and its effects on rat smooth muscle cells. J. Surg. Res. 157, e31-e37.
27. Moon, S.-K., Kim, H.-M. and Kim, C.-H. (2004) PTEN induces G1 cell cycle arrest and inhibits MMP-9 expression via the regulation of NF-κB and AP-1 in vascular smooth muscle cells. Arch. Biochem. Biophys. 421, 267-276.
28. Suh, S.-J., Jin, U.-H., Choi, H.-J., Chang, H. W., Son, J.-K., Lee, S. H., Jeon, S.-J., Son, K.-H., Chang, Y.-C. and Lee, Y.-C. (2006) Cryptotanshinone from Salvia miltiorrhiza BUNGE has an inhibitory effect on TNF-α-induced matrix metalloproteinase-9 production and HASMC migration via down-regulated NF-κB and AP-1. Biochem. Pharmacol. 72, 1680-1689.
29. Shishodia, S., Potdar, P., Gairola, C. G. and Aggarwal, B. B. (2003) Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24, 1269-1279.